Thank you for following us throughout 2024! What a year it’s been! We’ve shared knowledge, insights, and education on disease states and their management. We’re pausing for the holidays but will be back in January 2025 with even more!

While HbA1c levels <7% are recommended in #DiabetesCare,¹ achieving <6.5% (48 mmol/mol) within the first year of #T2D diagnosis minimize the risk of micro- and macrovascular complications.²

For patients with #Diabetes, the ADA/EASD consensus advocates for individualized care with optimized, tailored HbA1c targets when achievable with a low risk of hypoglycemia.¹

#T2D management should extend beyond just meeting HbA1c targets. This approach is due to the Egregious Eleven — the 11 key factors that cause hyperglycemia, which require multifactorial and holistic care.¹,² Follow us for more perspectives on #Diabetes

#T2D is recognized as a systemic dysfunction characterized by 11 key factors, known as the Egregious Eleven, that contribute to hyperglycemia. Effective #Diabetes management requires a multifactorial and holistic approach that goes beyond simply meeting HbA1c targets.¹,²

Management of #Diabetes aims to prevent complications and enhance quality of life and requires a focus beyond solely managing HbA1c levels. Follow our account for more insights like this!

Twice as many patients with #T2D reached a median FPG of <7.8 mmol/l (HbA1c 6.5%) through intensive management combined with diet modifications, compared to diet alone. As Dr. Vianna reminds, it’s important to not just start #DiabetesCare early but to start right.

What proportion of your patients with #T2D receive intensive management plus diet and exercise modifications? For HCPs.

Managing #T2D goes beyond diet and exercise, and dietary modifications alone may not prevent the progression or complications of #Diabetes. Ready to learn more? Follow us for continuous insights!

Dr. Vianna recognizes the value of personalized care in #T2D. This type of care with early intervention and a treat-to-target approach can address therapeutic inertia, and reduce the risk of #Diabetes complications.¹⁻³ Follow us for more perspectives from clinical practice!

In #T2D, treating-to-target rather than at the point-of-failure makes a difference. Evidence shows that early intervention helps achieve management goals, increases the durability of glycemic effect, addresses therapeutic inertia, and reduces the risk of complications.¹,²

The progressive nature of #T2D may result in managing patients at the point of failure or when glycemic control declines. But #DiabetesCare research tells a different story… ¹,²

Lilly proudly stands with the global diabetes community this #WorldDiabetesDay. We’re driven by our purpose: uniting caring and discovery to create medicines that make life better. Follow us for continuous updates.

Therapeutic inertia has been associated with a reduced quality of life for patients with #Type2Diabetes, along with increased risks of morbidity and mortality.¹ What strategies for improving #Diabetes care are you exploring in clinical practice?

We are thrilled to support the first-ever IDF-Europe Advocate Prize, recognizing outstanding advocates who made a real impact on the lives of people living with #Diabetes. Join us in honoring their contributions during the #WorldDiabetesDay celebrations!

Join us on #WorldDiabetesDay! It is an important opportunity to reflect on how diabetes impacts millions of lives. At Lilly, we have been committed to improving #DiabetesCare for more than a century. Follow us for more!

Over half a billion people around the globe live with diabetes. The prevalence of diabetes has grown in the last decade, but so has our commitment to helping people have a chance at better health. Our work to find new solutions for them is far from over. #WorldDiabetesDay

As #WorldDiabetesDay approaches, it’s important to prioritize the well-being of those living with diabetes. At Lilly, we are dedicated to innovative research and collaboration to make a meaningful impact in #DiabetesCare. Follow us for more insights on diabetes.

One day, we hope people living with diabetes will be free from the burden of their disease. But until we can achieve that goal, we remain committed to paving the way for a better diabetes care around the world. Together, we can make a difference. #WorldDiabetesDay

Exciting News! On #WorldDiabetesDay the International Diabetes Federation Europe, supported by Lilly, will be hosting two events at the EU Parliament to focus on advancing the conversation around #DiabetesCare and prevention.